Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 5Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Mesothelioma 1Lung Cancer Metastatic 1Breast Neoplasms 1

Interventions

tremelimumab 1regramostim 1osimertinib 1evolocumab 1durvalumab 1Surgical Instruments 1Radiotherapy 1Radiation 1Nivolumab 1Needles 1MLN 8237 1Ipilimumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Cancer Metastatic × MLN 8237 × Thoracic × Clear all
NCT04085315 2024-06-10

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

University of California, San Francisco

Phase 1 Recruiting
38 enrolled
Thoracic

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡